Abrams D, Schulze-Neick I, Magee A G
Department of Paediatric Cardiology, Royal Brompton & Harefield NHS Trust, Sydney Street, London SW3 6NP, UK.
Heart. 2000 Aug;84(2):E4. doi: 10.1136/heart.84.2.e4.
Primary pulmonary hypertension is a rare disease of childhood, which carries a poor prognosis. Patients often present with severe exercise limitation, and untreated life expectancy is less than 1 year. Pharmacological intervention is directed towards reduction of the raised pulmonary artery pressure with vasodilator treatment, initially with calcium antagonists, although more recently long term prostacyclin treatment has shown benefit in some patients. Heart-lung transplantation remains an option for children with severe disease refractory to therapeutic treatment. A 4 year old Bangladeshi girl with dyspnoea, cyanosis, and signs of a low cardiac output, is described. Initial treatment with prostacyclin was gradually reduced, and maintenance treatment with oral sildenafil (Viagra; Pfizer) instituted. At follow up 3 months later, her exercise capacity was greatly improved and she continues to enjoy a good quality of life without obvious side effects. In view of the encouraging initial results, this may become an acceptable adjunct in treating this patient group.
原发性肺动脉高压是一种罕见的儿童疾病,预后较差。患者常表现出严重的运动受限,未经治疗的预期寿命不到1年。药物干预旨在通过血管扩张剂治疗降低升高的肺动脉压力,最初使用钙拮抗剂,尽管最近长期前列环素治疗已在一些患者中显示出益处。心肺移植仍然是对治疗难治的重症患儿的一种选择。本文描述了一名4岁的孟加拉国女孩,她有呼吸困难、发绀和低心输出量的体征。最初使用前列环素的治疗逐渐减少,并开始使用口服西地那非(伟哥;辉瑞公司)进行维持治疗。3个月后的随访中,她的运动能力有了很大改善,并且继续享受着良好的生活质量,没有明显的副作用。鉴于令人鼓舞的初步结果,这可能成为治疗该患者群体的一种可接受的辅助手段。